Opendata, web and dolomites

MEsHH SIGNED

DNA MEthylation for HPV-related disease among women living with HIV

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MEsHH project word cloud

Explore the words cloud of the MEsHH project. It provides you a very rough idea of what is the project "MEsHH" about.

dna    enrolled    vili    alone    strategies    distinguish    stand    cancer    31    collected    pyrosequencing    endocervical    sensitivity    capacity    lesions    33    methylation    reported    positive    negative    matching    months    screening    predictive    ing       tests    markers    self    acid    africa    performed    shown    16    grade    progression    detection    via    data    referral    lugol    visual    predicting    follow    thereby    lesion    prevalent    1238    regression    south    coverage    virus    histological    inspection    assays    cin2    multiplex    18    neoplasia    persistence    swabs    incident    validation    carcinogenesis    hpv    cin    poor    prospective    intraepithelial    burkina    623    performance    cytology    meshh    hiv    wlhiv    previously    cervical    relevance    clinician    lacking    genes    iodine    overtreatment    615    faso    acetic    mal    primary    living    sa    mir    women    human    specificity    background    bf    colposcopy    hpv16    epb41l3    cadm1    combination   

Project "MEsHH" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE 

Organization address
address: AVENIDA GRAN VIA HOSPITALET 199-203
city: L'HOSPITALET DE LLOBREGAT
postcode: 8908
website: www.idibell.cat

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 158˙121 €
 EC max contribution 158˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-09-05   to  2020-09-04

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE ES (L'HOSPITALET DE LLOBREGAT) coordinator 158˙121.00

Map

 Project objective

Background: The current screening methods for cervical cancer screening among women living with HIV (WLHIV) have previously shown high sensitivity but poor specificity for the detection of high-grade cervical intraepithelial neoplasia (CIN2), resulting in over-referral for colposcopy and overtreatment of cervical lesions that may have low potential for progression to cancer. Methylation changes of human genes or HPV DNA have been reported early in carcinogenesis but their validation for predicting CIN among WLHIV is lacking. Objectives: Among 1238 WLHIV enrolled in Burkina Faso (BF; n=615) and South Africa (SA; n=623), the MesHH study aims to evaluate the performance of the DNA methylation of human genes (CADM1, MAL, MiR and EPB41L3) and HPV (HPV16/18/31/33) for the detection of prevalent and incident CIN2 compared to, or in combination with, other screening methods (visual inspection using acetic acid [VIA] or Lugol’s iodine [VILI], cytology and HPV DNA) and to evaluate the capacity of the DNA methylation markers to distinguish cervical lesion progression, persistence or regression at 16 months follow-up. Methods: The study will use endocervical swabs with matching histological data collected as part of a prospective study evaluating cervical cancer screening strategies among WLHIV in BF and SA. The DNA methylation assays for human genes (CADM1, MAL, MiR, EPB41L3) and HPV (HPV16/18/31/33) will be performed using pyrosequencing assays. Sensitivity, specificity, positive and negative predictive values for the detection of CIN2 will be estimated for the various DNA methylation markers, as stand-alone or multiplex tests. Relevance: Multiplex DNA methylation assays including a combination of human genes and HPV virus may have potential as primary screening for CIN2 among WLHIV. DNA methylation assays also have the potential to be performed using the same clinician- or self-collected sample used for cytology or HPV testing, thereby increasing screening coverage.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MESHH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MESHH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

ProTeCT (2019)

Proteasome as a target to combat trichomoniasis

Read More  

EuroDipl (2020)

European Diplomacy Practices post-Lisbon: Adding Value through Cooperation

Read More  

EGeoCC (2019)

Ethnic geography and civil conflict

Read More